Direct Oral Anticoagulants and Dementia Risk in Nonvalvular Atrial Fibrillation: Evidence to Guide Clinical Selection

from TheBrief.Health · host TheBrief.Health

Large real-world study found no meaningful dementia risk differences between apixaban, edoxaban, and rivaroxaban, supporting DOAC selection based on safety, adherence, renal function, and patient needs.

Episode metadata supplied by the publisher feed · Published Jun 30, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Direct Oral Anticoagulants and Dementia Risk in Nonvalvular Atrial Fibrillation: Evidence to Guide Clinical Selection

0:00 1:43

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on June 30, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!